济川药业(600566.SH)与康方签署伊努西单抗注射液独占性商业化权益协议

Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Kangfang Biopharmaceutical, allowing Jichuan to commercialize the PCSK9 monoclonal antibody drug, Inusimab injection, in China [1] Group 1: Agreement Details - Jichuan Pharmaceutical's wholly-owned subsidiary will pay a total of 80 million yuan (including tax) as an authorization fee to Kangfang [1] - Additionally, Jichuan will pay up to 10 million yuan (including tax) in milestone payments [1] Group 2: Product Information - Inusimab injection is an innovative drug developed by Kangfang, primarily used for treating primary hypercholesterolemia and mixed hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) [1] - The drug works by specifically binding to PCSK9 and blocking its interaction with low-density lipoprotein receptors (LDL-R), thereby restoring LDL-R expression levels to enhance the clearance of low-density lipoprotein cholesterol (LDL-C) from plasma [1] Group 3: Strategic Implications - The completion of this transaction is expected to enrich the product line of Jichuan Pharmaceutical, contributing to the sustainable development of the company's business [1]